Laurus Labs’ stock rose more than 5% in early trading after the US House of Representatives passed the Biosecure Act, which aims to strengthen the pharmaceutical supply chain and promote domestic domestic drug production. The news was well received by investors and major pharmaceutical firms saw rises in the market.
The stock stock opened at ₹495.90. The stock hit a day high of ₹518.00 and a low of ₹494.75. The company’s market capitalization reached ₹27,642.70 crore. Laurus Labs’s 52-week high is ₹518.00, while the 52-week low is ₹349.40.
The Biosecure Act is expected to provide Indian pharmaceutical companies with more benefits in the US market, which would boost the sector’s objectives.
As of 10:37 am, Laurus Labs shares were trading 3.82% higher at Rs 509.70 on the NSE.
